SEP 8, 2026 · JOURNAL ARTICLE
Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework
Frontiers in Oncology
A critical synthesis and clinical framework addressing heterogeneous stage III NSCLC management in the perioperative immunotherapy era, integrating recent phase III trial evidence with expert consensus on risk-adapted strategies.
Reported
Overall survival timepointfive years